THERAPY DOSSIER · th-b4736e550eef

Selegiline

Drug · Monoamine oxidase B inhibitor (INHIBITOR); irreversible inhibitor; direct interaction, disease efficacy true. ATC N04BD01. Black box warning present on the parent record. FDA label reference 021479.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Monoamine oxidase B inhibitor (INHIBITOR); irreversible inhibitor; direct interaction, disease efficacy true. ATC N04BD01. Black box warning present on the parent record. FDA label reference 021479.
Target: CHEMBL2039
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: 1989
Development stage: Not recorded
ChEMBL record: CHEMBL972 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: L-selegiline; L-deprenyl; Emsam; Eldepryl; Zelapar; Selegiline hydrochloride (CHEMBL1200904)
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00531596 ↗PHASE4completed

Phase IV open-label study of adhesion and dermal tolerability of EMSAM (selegiline transdermal system)

Healthy

Enrolment: 300 · Results not recorded

NCT00640159 ↗PHASE4completed

Switch from oral selegiline to orally disintegrating selegiline (Zelapar) in Parkinson's disease

Parkinson's Disease

Enrolment: 48 · Results not recorded

NCT00285766 ↗PHASE3completed

Phase III open-label safety, tolerability and efficacy of selegiline transdermal system in elderly with major depression

Major Depression

Enrolment: 300 · Results not recorded

NCT01912391 ↗PHASE3completed

Phase III trial of transdermal selegiline in borderline personality disorder

Borderline Personality Disorder

Enrolment: 30 · Results not recorded

NCT00439413 ↗PHASE2completed

Phase 2 trial of selegiline transdermal system as an aid for smoking cessation

Nicotine Dependence

Enrolment: 246 · Results not recorded

NCT00002154 ↗PHASE2completed

Tolerability and safety of thioctic acid and deprenyl in HIV dementia

Cognitive Disorders · HIV Infections

Enrolment: 32 · Results not recorded

NCT00000201 ↗PHASE2completed

Pharmacological modulation of cocaine effects (selegiline)

Cocaine-Related Disorders

Enrolment: 0 · Results not recorded

NCT00000337 ↗PHASE1completed

Infusion Laboratory: Protocol 1 - Selegiline

Cocaine-Related Disorders

Enrolment: 0 · Results not recorded

NCT05938517 ↗PHASE1completed

PK-BeST: betahistine serum concentration with and without selegiline in healthy volunteers

Meniere's Disease

Enrolment: 15 · Results not recorded

NCT00027040 ↗NAcompleted

HIV-associated cognitive impairment and oxidative stress: in vivo proton MRS study (selegiline hydrochloride)

Cognitive Disorders · HIV Infections

Enrolment: 90 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30712291 ↗2019Mixed findings

Adjuvant potential of selegiline in treating acute toxicity of aluminium phosphide in rats.

RatChemical/toxinMaleIntraperitoneal injection1 h after aluminium phosphide poisoning

Model: Acute aluminium phosphide poisoning induced by oral gavage, releasing phosphine gas and causing cardiac and gastrointestinal toxicity

Selegiline did not significantly change mortality after aluminium phosphide poisoning, but it reduced cardiac reactive oxygen species and malondialdehyde, increased glutathione, reversed the collapse of mitochondrial membrane potential, improved electrocardiographic parameters and heart rate, and r…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…